

Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

LOCOREGIONAL	FIRST LINE	SECOND LINE	THIRD LINE
<u>UCI 19-49</u> Cabo + Ipi/Nivo + TACE Coord: B. Nguyen Accrual: 24/35	<u>UCI 22-106</u> STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab (Slot request required) Coord: H. Nguyen Accrual: 9/10	<u>UCI 16-94</u> TATE + Nivolumab (includes gastric/GEJ) Coord: S. Duong Accrual: 34/48	
<u>UCI 23-75/ROUTE 90</u> Eye90 microspheres Coord: B. Nguyen Accrual: 3/15	<u>UCI 22-211</u> MED1572 (IgG1 mAb) ± Bev Suspended for additional cohort Coord: B. Nguyen Accrual: 3/8	<u>UCI 23-215</u> AZD5851 (GPC3 Autologous CAR-T) Central testing for GPC3 and no previous GPC3 treatment Suspended until at least Q1 2026	
ADJUVANT <u>UCI 25-136</u> Personalized Neoantigen DNA Vaccine (GNOS-PV02) vs. Surveillance High-Risk HCC DOT approved	<u>UCI 23-104</u> Livmoniplimab + Budigalimab Atezolizumab + Bevacizumab Tremelimumab + Durvalumab Suspended until Q4 2025 Coord: S. Duong Accrual: 3/7	<u>UCI 25-06</u> ABBV-324 (GPC3 ADC) vs. Lenvatinib Coord: M. Duron Accrual: 1/3	<u>UCI 24-09</u> RYZ801 (GPC3 radiotherapeutic) Pending qualification, SIV 9/22/25



■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

SYSTEMIC + OPERATIVE

ETCTN 10608
 Gemcitabine + Cisplatin +
 Durva Neo/Adjuvant for **high-risk resectable ICC**

Reopen September 2025
 Coord: H. Nguyen
 Accrual: 2/3

UCI 23-99
 Randomize, adjuvant
 Rilvegostomig/placebo +
 capecitabine or gem/cisplatin
 after BTC resection

Coord: B. Nguyen
 Accrual: 1/8

FIRST LINE

UCI 22-211
MED1572 (IgG1 mAb) or
AZD2936 (TIGIT) ±
gemcitabine and cisplatin

TBD more slots to be released

Coord: B. Nguyen
 Accrual: 3/8

SECOND LINE+


ETCTN-10276
 M3814 ± Avelumab +
 Hypofraction Radiation

Coord: C. Kang
 Accrual: 3/5

UCI 23-200
 AZD0901 (CLND18 ADC)
Central prescreening

Suspended until Q1 2026
 Coord: M. Duron
 Accrual: 5/10

UCI 25-137
 Nanvuranlat (LAT1 inhibitor)
 vs. Physician choice
 chemotherapy
 DOT approved





ADJUVANT

S2104

Capecitabine + Temozolomide vs observation

Pancreatic NET Ki67 > 3%

Coord: J. Balangue
Accrual: 0/2

SECOND LINE

ETCTN 10479

Lu-177 + Sunitinib

Well or moderately differentiated PNET
Up to one line of systemic therapy not including somatostatin

Coord: H. Nguyen
Accrual: 0/3

SECOND LINE+

ETCTN 10558

Lu-177 ± Triapine

NET w/positive 68 or 64 DOTATATE on scans

Coord: H. Nguyen
Accrual: 3/3

METASTATIC

UCI 24-138

Various Neuroendocrine including Gastroenteropancreatic NEN with DLL3 expression

PRMC approved

UCI 25-75

NET/NEC solid tumors with SST2 expression

Pending IRB/Budget/CTA

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

Open to Accrual

Low Accruing

Pending Activation/Suspended

CLAUDIN 18.2

UCI 22-51

ASP2138 (CLDN18.2 BiTe)

Pancreatic and Gastric/GEJ

Coord: P. Yang
Accrual: 31/35

AKT1 E17K

UCI 25-28

ATV-1601 (ATK Inhibitor)

ATK1 E17K local testing

PRMC approved

KRAS/NRAS

UCI 21-53

LY3537982 (KRAS G12C Inhibitor)

Coord: J. Choe
Accrual: 9/12

GERMLINE MUTATIONS

ETCTN-10528

Novobiocin (POLθ)
Germline mutations

Coord: H. Nguyen
Accrual: 0/5

MTAP

UCI 24-197

TNG456 (PRMT5 inhibitor)

MTAP NGS/IHC local testing

PRMC approved

TP53-Y220C

UCI 25-52

Rezatapopt (p53 reactivator)

TP53 Y220C local testing

PRMC approved

UCI 22-87

RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS WT 2L

Coord: C. Kang
Accrual: 21/25

ALK

UCI 21-241

NVL- 655

Coord: J. Balanguie
Accrual: 20/25

Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: B. Nguyen
Accrual: 11/12

UCI 24-142

VET3-TGI (IL-12 and TGF- β inhibiting vaccine) $\pm$
Pembrolizumab
Intra-tumoral or IV

All solid tumors

Accrual: 0/4

UCI 25-16

ODM-212 (Hippo pathway)

Reach out to coordinator for
selected tumor types
(9/10/25 accepting PDAC)

Coord: P. Yang

BLOOD COLLECTION

UCI 21-124

ctDNA collection during HBP workup

Coord: J. Balangué

Accrual: 16/17

UCI 23-10/PRECEDE

(Blood collection for early detection of pancreatic cancer)

Pending budget/contract

UCI 22-55

Blood and biomarker collection for early detection and diagnosis of DNA Deficient Hereditary Cancers

Investigators: Dr. Jennifer Valerin and Dr. Nicholas Pannunzio